Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7200220 in Uveitic Macular Edema
2022-501794-39-00Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of vamikibart in uveitic macular edema (UME) and noninfectious uveitis (NIU) (2 arms), sponsored by Roche. Primary endpoint: Proportion of participants with ≥15 letter improvement from baseline in BCVA at Week 16. Started Jun 2023; status: completed.
02
Drugs
vamikibart
03
Conditions
uveitic macular edema (UME)noninfectious uveitis (NIU)
Beyond the preview
Go deeper on 2022-501794-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501794-39-00.